ALLOAllogene Therapeutics, Inc.

Nasdaq allogene.com


$ 2.98 $ 0.06 (2.07 %)    

Tuesday, 14-May-2024 15:59:49 EDT
QQQ $ 445.88 $ 2.85 (0.64 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.39 (0.46 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 2.96
$ 2.98
$ 0.00 x 0
$ 0.00 x 0
$ 2.72 - $ 2.99
$ 2.23 - $ 6.89
8,451,502
na
500.62M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 03-08-2019 12-31-2018 10-K
23 11-21-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-maintains-hold-on-allogene-therapeutics-raises-price-target-to-46

Stifel analyst Benjamin Burnett maintains Allogene Therapeutics (NASDAQ:ALLO) with a Hold and raises the price target from $...

 allogene-therapeutics-q1-2024-gaap-eps-038-beats-041-estimate-sales-22000k-down-from-30000k-yoy

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of...

 allogene-therapeutics-awarded-15m-grant-from-california-institute-for-regenerative-medicine-to-advance-development-of-allogeneic-car-t-in-renal-cell-carcinoma

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic ...

 hc-wainwright--co-reiterates-buy-on-allogene-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $10 pri...

 rbc-capital-reiterates-outperform-on-allogene-therapeutics-maintains-10-price-target

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.

 allogene-therapeutics-q4-2023-gaap-eps-051-misses-046-estimate-sales-21000k-miss-23571k-estimate

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 allogene-therapeutics-and-arbor-biotechnologies-announce-global-gene-editing-licensing-agreement-to-support-advancement-of-next-generation-allogeneic-car-t-platform-in-autoimmune-disease

Allogene's AlloCAR T™ Autoimmune Disease Platform Leverages Arbor's CRISPR Gene-Editing Technology First Allogeneic CAR...

 jp-morgan-maintains-overweight-on-allogene-therapeutics-lowers-price-target-to-8

JP Morgan analyst Brian Cheng maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and lowers the price target fr...

 allogene-therapeutics-to-restate-previously-filed-financial-statements-related-to-the-december-2020-formation-of-the-allogene-overland-biopharm-joint-venture-in-asia-no-impact-on-cash-cash-equivalents-and-marketable-investments-cash-runway-or-business-operations

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Befo...

 cymabay-therapeutics-contextlogic-snap-and-other-big-stocks-moving-higher-on-monday

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ...

 hc-wainwright--co-maintains-buy-on-allogene-therapeutics-lowers-price-target-to-10

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price t...

 cell-therapy-focused-allogene-therapeutics-resource-prioritization-a-bold-move-says-analyst

Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND ...

 why-applied-therapeutics-shares-are-trading-lower-by-over-35-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Applied Therapeutics, Inc.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION